Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigen

Clinical Infectious Diseases

Volumn 50, Issue 8, 2010, Pages 1184-1186

  Chakvetadze, Catherine ^a   Bani Sadr, Firouzé ^a   Catherine, Le Pendeven ^a   Lescure, François Xavier ^a   Fontaine, Camille ^a   Galperine, Tatiana ^a   Slama, Laurence ^a   Bonnard, Philippe ^a   Mariot, Philippe ^a   Soussan, Patrick ^a   Pialoux, Gilles ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; LAMIVUDINE; RECOMBINANT HEPATITIS B VACCINE; TENOFOVIR;

ADULT; ANTIBODY ISOLATION; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG SAFETY; FEMALE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SEROLOGY; TREATMENT RESPONSE; VACCINATION;

ADULT; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED;

EID: 77950209220     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651422     Document Type: Article

References (18)

1. Piroth L, Lafon ME, Binquet C, et al. Occult hepatitis B in HIV-HCV coinfected patients. Scand J Infect Dis 2008;40:835-839.
2. French AL, Operskalski E, Peters M, et al. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis 2007; 195: 1437-1442.
3. Neau D, Winnock M, Galperine T, et al. Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. HIV Med 2004; 5:171-173.
4. Gandhi RT, Wurccl A, Lee H, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005; 191:1435-1441.
5. Quaglio G, Lugoboni F, Vento S, et al. Isolated presence of antibody to hepatitis B core antigen in injection drug users: do they need to be vaccinated? Clin Infect Dis 2001;32:e143-e144.
6. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615-624.
7. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical, management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9:82-88.
8. Bocher WO, Herzog-Hauff S, Schlaak J, Meyer zum Buschenfeld KH, Lohr HF. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Hepatology 1999;29:238-244.
9. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients: effects on HIV-I viral load. Vaccine 2000; 18:1161-1165.
10. McMahon BJ, Parkinson AJ, Helminiak C, et al. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. Gastroenterology 1992; 103:590-594.
11. Silva AE, McMahon BJ, Parkinson AJ, Sjogren MH, Hoofnagle JH, Di Bisceglie AM. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin Infect Dis 1998;26:895-897.
12. Cruciani M, Mengoli C, Serpelloni G, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009;27:17-22.
13. Kabir A, Kcshvari M, Kashani AH, Alavian SM. Predicting response to HBV vaccination in people with positive anti-HBc but negative HBsAg and anti-HBs. Hum Vaccin 2008;4:379-383.
14. Winter AP, Follett EA, McIntyre J, Stewart J, Symington IS. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 1994; 12:771-772.
15. Launay O, Grabar S, Gordien E, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr 2008;49:272-275.
16. Rosman AS, Basu P, Galvin K, Lieber CS. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med 1997; 103:217-222.
17. Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004;39:1207-1213.
18. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008;46:1310-1314.